Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis

Highlights: • SABR in oligometastatic breast cancer is safe and correlated with high rates of local control. • In the meta-regression analysis prospective design (p = 0.001) and bone-only metastases (p = 0.01) were significantly associated with better OS. • Hormone receptor status was associated with improved local control (p = 0.01) on meta-regression analysis. • Longer follow-up of existing data and ongoing prospective trials will help further define the role of this management strategy. Stereotactic ablative radiotherapy (SABR) has been reported to be an effective treatment for oligometastatic disease from different primary cancer sites. Here we assess the effectiveness and safety of SABR for oligometastatic breast cancer patients by performing a meta-analysis.